Filing Flows › 8-K events › ANI Pharmaceuticals
ANI Pharmaceuticals: entry into a material definitive agreement
Form 8-K filed Nov 5, 2026 · items 1.01, 2.03, 8.01
What the filing says
On Novemb er 4, 2 026, ANI Pharmaceuticals, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) relating to a 364-day senior bridge facility (the “Facility”), with the lenders named therein and JPMorgan Chase Bank, N.A, as administrative agent. The Facility provides for borrowings up to an agg
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Item 8.01: +0.1% next session across 44,881. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.
ANI Pharmaceuticals at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%. The chart follows the revenue to costs, profit and cash.
ANI Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
ANI Pharmaceuticals’s other material 8-Ks
- Nov 5, 2026 — FDA decisions ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results
Other recent debt and financing
- Airsculpt Technologies Nov 6, 2026
- Starry Sea Acquisition Nov 6, 2026
- Repligen Nov 6, 2026
- Evertec Nov 6, 2026
- Clean Energy Technologies Nov 6, 2026
- Reed's Nov 6, 2026
- Protagenic Therapeutics, Inc.\new Nov 6, 2026
- CNL Strategic Residential Credit Nov 6, 2026
- Health In Tech Nov 6, 2026
- Profusa Nov 6, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.